Codexis Inc. Common Stock (CDXS)
Stock · NASDAQ · Industrials
$1.24as of 10/16/2026
Price chart
Active signals
CDXS Signal Track Record
How signals performed across all stocks →What CDXS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | -2.9% | 47% | September 16, 2026 |
| Bollinger Band Breakout | 25 | -10.7% | 32% | August 21, 2026 |
| Bollinger Band BreakdownActive now | 20 | -5.9% | 40% | July 14, 2026 |
| 200-Day Moving Average TouchActive now | 6 | +12.0% | 83% | July 23, 2026 |
| Any 20-session window (baseline) | -3.6% | 43% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CDXS
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scale…
- Sector
- Industrials
- Industry
- Major Chemicals
- Employees
- 146
- Website
- www.codexis.com/
Fundamentals
- 1-day range
- $1.22$1.36
- Market cap
- $134.53M
- P/E (trailing)
- —
- P/E (forward)
- -3.88
- EPS (trailing)
- $-0.34
- Dividend yield
- —
- Beta
- 2.38
- Avg. volume
- 1.14M
How Codexis Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Feb 27, 2025 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
Codexis Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CDXSCodexis Inc. Common Stock$1.24▼ 8.82%Market cap $134.53MP/E —$0.96$2.98
- ACNTAscent Industries Co. Common Stock$13.49▼ 0.44%Market cap $137.39MP/E 112.24$11.86$17.92
- SAFXXCF Global Inc. Class A Common Stock$0.14▼ 17.16%Market cap $148.22MP/E 2.85$0.119$1.32
- AMTXAemetis Inc. (DE) Common Stock$1.46▲ 1.04%Market cap $114.70MP/E —$1.3$3.8
- ARQArq Inc. Common Stock$1.79▼ 3.76%Market cap $90.57MP/E —$1.54$7.24
- FSIFlexible Solutions International Inc. Common Stock (CDA)$6.05▲ 0.67%Market cap $64.25MP/E 76.65$4.85$9.89
- LNZALanzaTech Global Inc. Common Stock$4.62▲ 3.82%Market cap $61.85MP/E 0.34$4.3$44
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CDXS Codexis Inc. Common Stock | $134.53M | — | $1.24 | ▼ 8.82% | $0.96$2.98 |
| ACNT Ascent Industries Co. Common Stock | $137.39M | 112.24 | $13.49 | ▼ 0.44% | $11.86$17.92 |
| SAFX XCF Global Inc. Class A Common Stock | $148.22M | 2.85 | $0.14 | ▼ 17.16% | $0.119$1.32 |
| AMTX Aemetis Inc. (DE) Common Stock | $114.70M | — | $1.46 | ▲ 1.04% | $1.3$3.8 |
| ARQ Arq Inc. Common Stock | $90.57M | — | $1.79 | ▼ 3.76% | $1.54$7.24 |
| FSI Flexible Solutions International Inc. Common Stock (CDA) | $64.25M | 76.65 | $6.05 | ▲ 0.67% | $4.85$9.89 |
| LNZA LanzaTech Global Inc. Common Stock | $61.85M | 0.34 | $4.62 | ▲ 3.82% | $4.3$44 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNAYahoo · 9/28/2026
- Codexis Enters Agreement With An Unnamed siRNA Drug Innovator To Explore Stereo-Defined Fragment Synthesis Using Its ECO Synthesis Manufacturing PlatformBenzinga · 9/28/2026
- What Needs To Be True To Buy Twist Bioscience Stock Now?Yahoo · 9/25/2026
Insider Activity
Insider Actions →- H. Stewart Parker · June 17, 2026 · Grant66.3K
- Cynthia Collins · June 17, 2026 · Grant66.3K
- Christos Richards · June 17, 2026 · Grant66.3K
- David Smith V · June 17, 2026 · Grant66.3K
- Rahul Singhvi · June 17, 2026 · Grant66.3K
- Esther Martinborough · June 17, 2026 · Grant66.3K
- Stephen George Dilly · June 17, 2026 · Grant66.3K
- De Vre Raymond · June 17, 2026 · Grant66.3K
- De Vre Raymond · June 11, 2026 · Sale2.6K @ $2.37
Institutional Ownership
March 31, 2026
- Total shares held
- 64.00M
- Total value held
- $103.51M
- Institutional holders
- 129
- Unknown8.68M
- Unknown7.03M
- Unknown6.79M
- Unknown4.12M
- Unknown4.00M
- Unknown3.85M
- Unknown3.67M
- Unknown3.40M
- Unknown2.18M
- Unknown1.89M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Codexis Signs siRNA Manufacturing Deal
Codexis has entered an agreement with an unnamed siRNA drug innovator to use its ECO Synthesis platform for stereo-defined fragment synthesis. This partnership highlights the company's manufacturing capabilities in a growing therapeutic area. The stock is currently trading near its 52-week low, with recent price action showing rejection at support levels.
Codexis Signs siRNA Manufacturing Deal. Codexis has entered an agreement with an unnamed siRNA drug innovator to use its ECO Synthesis platform for stereo-defined fragment synthesis. This partnership highlights the company's manufacturing capabilities in a growing therapeutic area. The stock is currently trading near its 52-week low, with recent price action showing rejection at support levels.